In liver transplant patients, chronic
immunosuppression increases the
risk of acquiring COVID-19 but it
could reduce disease severity. Com-
plete immunosuppression with-
drawal may not be justified. However,
mycophenolate withdrawal or tem-
porary conversion to calcineurin
inhibitors or everolimus until disease
resolution could be beneficial in hos-
pitalised patients